Previous 10 | Next 10 |
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia PR Newswire CUPERTINO, Calif. , Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its boar...
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit PR Newswire CUPERTINO, Calif. , Nov. 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the ...
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S. AH hospitalizations increased by approximately 4.8% per year between 2015 and 2018 Approximately 80% of AH patients who died while h...
DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis PR Newswire CUPERTINO, Calif. , Nov. 10, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed...
DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021 PR Newswire CUPERTINO, Calif. , Nov. 8, 2021 /PRNewswire/ -- DURECT Corpora...
DURECT Corporation (DRRX) Q3 2021 Earnings Conference Call November 2, 2021 16:30 ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President and Chief Executive Officer Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzg...
DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs -Earnings Call and Webcast Today, November 2nd at 4:30 p.m. ET -Expanded number of AHFIRM study sites -Opened first ex-US AHFIRM study sites -Advanced POSIMIR licensing process ...
ADC, AFG, DADA, AIZ, AKAM, AMCR, AMED, AMGN, ANDE, APPS, AQST, ATVI, AWK, AYX, BFAM, BGFV, BKH, BTG, BXC, CASA, CDK, CDLX, CERS, CGBD, CHCT, CHK, CLW, COUR, CRK, [CSLT]], CVGI, CZR, DCP, DCPH, DENN, DHT, DOX, DRRX, [DVN]], EARN, EGHT, EIX, EKSO, ELVT, ENLC, EXAS, EXEL, FMC, FNF, FRG, GAIN, GN...
Durect (NASDAQ:DRRX) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close. The consensus EPS Estimate is -$0.05 (flat Y/Y) and the consensus Revenue Estimate is $1.95M (-27.2% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 do...
Gainers: G Medical Innovations (NASDAQ:GMVD) +15%, Accuray (NASDAQ:ARAY) +14%, Xeris Biopharma (NASDAQ:XERS) +9%, DURECT (NASDAQ:DRRX) +9%, Ocugen (NASDAQ:OCGN) +7%. Losers: CareDx (NASDAQ:CDNA) -25%, 4D Molecular Therapeutics (NASDAQ:FDMT) -2...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...